HDAC6 inhibition enhances 17-AAG mediated abrogation of hsp90 chaperone function in human leukemia cells

Blood

Volumn 112, Issue 5, 2008, Pages 1886-1893

  Rao, Rekha ^a   Fiskus, Warren ^a   Yang, Yonghua ^a   Lee, Pearl ^a   Joshi, Rajeshree ^a   Fernandez, Pravina ^a   Mandawat, Aditya ^a   Atadja, Peter ^b   Bradner, James E ^c   Bhalla, Kapil ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BCR ABL PROTEIN; CHAPERONE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 6; PROTEIN KINASE B; PROTEIN P23; RAF PROTEIN; SMALL INTERFERING RNA; TANESPIMYCIN; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; HDAC6 PROTEIN, HUMAN; HISTONE DEACETYLASE; MACROCYCLIC LACTAM;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BINDING AFFINITY; CELL SURVIVAL; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; ACETYLATION; CELL STRAIN HL 60; CELL STRAIN K 562; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MYELOID LEUKEMIA; NUCLEOTIDE SEQUENCE;

ACETYLATION; ADENOSINE TRIPHOSPHATE; BASE SEQUENCE; BENZOQUINONES; CELL SURVIVAL; FUSION PROTEINS, BCR-ABL; HISTONE DEACETYLASES; HL-60 CELLS; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; K562 CELLS; LACTAMS, MACROCYCLIC; LEUKEMIA, MYELOID; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RAF; RNA, SMALL INTERFERING;

EID: 52649133274     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-143644     Document Type: Article

References (44)

1. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood). 2003;228:111-133.
2. Neckers LJ. Heat shock protein 90: the cancer chaperone. J Biosci. 2007;32:517-530.
3. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5:761-772.
4. Ali MM, Roe S, Vaughan CK, et al. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature. 2006;440:1013-1017.
5. Shiau AK, Harris SF, Southworth DR. Agard D. Structural analysis of E. coli hsp90 reveals dramatic nucleotide-dependent conformational rearrangements. Cell. 2006;127:329-340.
6. Meyer P. Prodromou C, Hu B, et al. Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. Mol Cell. 2003;11:647-658.
7. Cintron N. Toft D. Defining the requirements for Hsp40 and Hsp70 in the Hsp90 chaperone pathway. J Biol Chem. 2006281:26235-26244.
8. Roe SM, Ali MM. Meyer P, et al. The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell. 2004;116:87-98.
9. Grenert JP, Sullivan WP, Fadden P, et al. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem. 1997;272:23843-23850.
10. Nimmanapalli R, O'Bryan E, Kuhn D, Yamaguchi H, Wang HG, Bhalla KN. Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAG-mediated downregulation of Akt, Raf-1, and Src kinases. Blood. 2003;102:269-275.
11. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 2001;61:1799-1804.
12. Bonvini P, Gastaldi T, Falini B, Rosolen A. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino, 17-demethoxygeldanamycin. Cancer Res. 2002;62:1559-1566.
13. George P, Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human GML-BG cells and AML cells with activating mutation of FLT-3. Blood. 2005;105: 1768-1776.
14. Vaughan CK, Gohlke U, Sobott F, et al. Structure of an Hsp90-Cdc37-Cdk4 complex. Mol Cell. 2006;23:697-707.
15. Peng C, Brain J, Hu Y, et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T3151-induced leukemia and suppresses leukemic stem cells. Blood. 2007;110: 678-685.
16. Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005;280: 26729-26734.
17. Zhang X, Yuan Z, Zhang Y, et al. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell. 2007;27:197-213.
18. Kovacs JJ, Murphy PJ, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperonedependent activation of glucocorticoid receptor. Mol Cell. 2005;18:601-607.
19. Nimmanapalli R, Fuino L, Bali P, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003;63:5126-5135.
20. Bali P, George P, Cohen P, et al. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res. 2004;10:4991-4997.
21. Fiskus W, Pranpat M, Balasis M, et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther. 2006;5:3096-3104.
22. Kamal A, Thao L, Sensintaffar J, et al. Ahighaffinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003;425: 407-410.
23. National Center for Biotechnology Information. Entrez Nucleotide, http://www.ncbi.nlm.nih.gov/GenBank. Accessed July 25, 2008.
24. Beer S, Zetterberg A, Ihrie RA, et al. Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol. 2004;2:1785-1798.
25. Yang Y, Rao R, Shen J, et al. Role of acetylation and extracellular location of heat shock protein 90a in tumor cell invasion. Cancer Res. 2008;68: 4833-4842.
26. Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of smallmolecule histone deacetylase inhibitors. Biochem J. 2008;409:581-589.
27. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective smallmolecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A. 2003; 100:4389-4394.
28. HideshimaT, Bradner JE. Wong J, et al. Smallmolecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005;102:8567-8572.
29. Fiskus W, Ren Y, Mohaptra A, et al. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res. 2007;13:4882-4890.
30. Chen L, Meng S, Wang H, et al. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther. 2005;4:1311-1319.
31. Bali P, Pranpat M, Swaby R, et al. Activity of suberoylanilide hydroxamic acid (SAHA) against human breast cancer cells with amplification of Her-2. Clin Cancer Res. 2005;11:6382-6389.
32. McLaughlin SH, Sobott F, Yao Z, et al. The cochaperone p23 arrests the Hsp90 ATPase cycle to trap client proteins. J Mol Biol. 2006;356:746-758.
33. Karnitz LM. Felts SJ. Cdc37 regulation of the kinome: when to hold 'em and when to fold 'em. Sci STKE. (http://stke. sciencemag.org/2007: pe22 (DOI 10.1126/stke.3852007pe22).
34. Scroggins BT, Robzyk K. Wang D, et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell. 2007;25:151-159.
35. Yang Y, Bhalla K. Identification and role of lysine acetylation sites in regulating chaperone function of heat shock protein 90α. Proc Amer Assoc Cancer Res. 2007;48:170-171.
36. Aoyagi S, Archer TK. Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol. 2005;15:565-567.
37. Boyault C, Sadoul K. Pabion M. Khochbin S. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene. 2007;26:5468-5476.
38. Zhang Y, Kwon S. Yamaguchi T et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol. 2008;28:1688-1701.
39. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 2003; 115:727-738.
40. Boyault C, Zhang Y Fritah S, et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev. 2007:21:2172-2181.
41. Westerheide SD, Morimoto Rl. Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem. 2005;280:33097-33100.
42. Mimnaugh EG, Xu W, Vos M, et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther. 2004;3:551-566.
43. Davenport EL, Moore HE, Dunlop AS, et al. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood. 2007;110:2641-2649.
44. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7:585-598.